Home-Delivered Attention Control Treatment for Post Traumatic Stress Disorder (PTSD)

Sponsor
Tel Aviv University (Other)
Overall Status
Completed
CT.gov ID
NCT04228133
Collaborator
(none)
60
1
2
15.1
4

Study Details

Study Description

Brief Summary

The aim of the study is to explore the efficacy of home-delivered Attention Control Training (ACT) for Posttraumatic Stress Disorder (PTSD).

Three randomized controlled trials have shown that attention bias modification protocols applying attention control training (ACT) aimed to balance attention between threat-related and neutral stimuli are efficient in reducing PTSD symptoms. However, contrary to in-clinic administration, such as applied in the above mentioned studies, home-delivered attention bias modification was not effective in reducing symptoms among treatment-seeking patients.

It is crucial to continue examining the efficacy of home-delivered ACT as PTSD entails functional impairments that might impede treatment-seeking patients from reaching to clinics to receive treatment. This could also inform other ABM protocols designated to treat other disorders.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Attention Control Training (ACT)
  • Behavioral: Attention Bias Modification (ABM)
N/A

Detailed Description

The aim of the study is to explore the efficacy of home-delivered Attention Control Training (ACT) for Posttraumatic Stress Disorder (PTSD).

Three randomized controlled trials have shown that attention bias modification (ABM) protocols applying attention control training (ACT) aimed to balance attention between threat-related and neutral stimuli are efficient in reducing PTSD symptoms. However, contrary to in-clinic administration, such as applied in the above mentioned studies, home-delivered ABM was not effective in reducing symptoms among treatment-seeking patients.

It is crucial to continue examining the efficacy of home-delivered ACT as PTSD entails functional impairments that might impede treatment-seeking patients from reaching to clinics to receive treatment. This could also inform other ABM protocols designated to treat other disorders.

To overcome some critical differences between home and lab environments, the investigators developed a home-delivered ACT protocol that resembles as much as possible the typical-in-lab protocol. Specifically, participants will be accompanied during their training sessions using internet-based video conference, permitting a better control for the physical environment before and during the session and a direct interaction with the experimenters.

To test its efficacy, the investigators will recruit participants that are diagnosed with PTSD and will be randomly assigned to one of two home-delivered conditions: ACT and a control ABM condition. It is hypothesized that home-delivered ACT will produce greater reduction in PTSD symptoms relative to a control ABM protocol. It is also expected that ACT will reduce attention bias variability to a greater extent compared to the control condition.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Home-Delivered Attention Control Training for Post Traumatic Stress Disorder: A Randomized Controlled Trial
Actual Study Start Date :
Jan 1, 2020
Actual Primary Completion Date :
Apr 5, 2021
Actual Study Completion Date :
Apr 5, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Home-delivered attention control training (ACT)

A home-delivered ACT comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV).

Behavioral: Attention Control Training (ACT)
A home-delivered version of ACT will be administered in this study. ACT will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe replaces the neutral and threat stimuli with an equal probability to reduce attention bias variability (ABV). In addition, sessions will include video conference with the experimenter. This condition has found to be more effective in PTSD symptom reduction compared to ABM.

Placebo Comparator: Home-delivered attention bias modification (ABM)

A home-delivered ABM comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat.

Behavioral: Attention Bias Modification (ABM)
A home-delivered version of ABM will be administered in this study. ABM will be comprised of 8 sessions with a variation of the dot-probe task in which the target probe always replaces the threat stimuli to induce diversion of attention away from threat. In addition, sessions will include video conference with the experimenter. This condition has found to be have an inferior effect on PTSD symptom reduction compared to ACT, and thus, this ABM condition has been chosen as a control condition.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline of the total severity score of the CAPS-5 interview [up to 2 weeks pre-treatment and 1-2 weeks post-treatment]

    The Clinician Administered PTSD Scale (CAPS-5), is a structured interview that will be used to make a diagnosis of PTSD according to the DSM-V criteria. This interview is consists of 30 items regarding the frequency and intensity of PTSD symptoms and a total score of severity is been rated, with higher scores denoting higher symptom severity.

Secondary Outcome Measures

  1. Change from baseline of the total score of the PTSD Checklist (PCL-5) [up to 2 weeks pre-treatment and 1-2 weeks post-treatment]

    The PCL-5, is a 20-item National Center for PTSD Checklist of the Department of Veterans Affairs. Scores can range from 0 to 80, with higher scores reflecting more symptoms of PTSD.

Other Outcome Measures

  1. Change from baseline of the total score of the PHQ-9 [up to 2 weeks pre-treatment and 1-2 weeks post-treatment]

    The PHQ-9 is a 9-item scale for depression symptoms (Kroenke, Spitzer, & Williams, 2001). Scores can range from 0 to 27, with higher scores reflecting more symptoms of depression.

  2. The Credibility/Expectancy Questionnaire (CEQ) [up to 2 weeks pre-treatment and 1-2 weeks post-treatment]

    The Credibility/Expectancy Questionnaire (CEQ; Devilly & Borkovec, 2000). This instrument consists of 6 items which derive two factors: expectancy for change and treatment credibility. This CEQ will be used to explore whether expectancies or treatment credibility are related to outcomes. It demonstrated high internal consistency and good test-retest reliability.

  3. The CGI/S [up to 2 weeks pre-treatment and 1-2 weeks post-treatment]

    Severity and improvement scales (CGI-S/I) will be used to assess participants global clinical condition. The CGI-S and the CGI-I are single-items, clinician-reported, measure assessing severity and improvement of illness using a 7-point Likert-type scale. The CGI-S/I has good inter-rater reliability and concurrent validity with other measures. This tool is widely used in clinical trials concerning psychopathology treatments and has good sensitivity to clinical change.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meeting a current diagnosis of Post-Traumatic Stress Disorder (PTSD) according to DSM-V (American Psychiatric Association, 2013);

  • Having a home PC with internet access, web cam, microphone and speakers. Operation system must be windows 7 or a newer version.

Exclusion Criteria:
  • A diagnosis of psychotic or bipolar disorders.

  • A diagnosis of a neurological disorder (i.e., epilepsy, brain injury).

  • Suicidal ideation.

  • Drugs or alcohol abuse.

  • Non-fluent Hebrew.

  • A pharmacological or psychotherapy treatment that is not stabilized in the past 3 months (a stable treatment will not be a reason for exclusion from the study).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tel Aviv University Tel Aviv Israel 6997801

Sponsors and Collaborators

  • Tel Aviv University

Investigators

  • Principal Investigator: Yair Bar-Haim, PhD, Tel Aviv University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yair Bar-Haim, Professor of Psychology and Neuroscience School of Psychological Sciences Sagol School of Neuroscience Tel Aviv University, Tel Aviv University
ClinicalTrials.gov Identifier:
NCT04228133
Other Study ID Numbers:
  • TAU-ACT
First Posted:
Jan 14, 2020
Last Update Posted:
Apr 6, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yair Bar-Haim, Professor of Psychology and Neuroscience School of Psychological Sciences Sagol School of Neuroscience Tel Aviv University, Tel Aviv University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2021